52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Nektar Therapeutics Q2 Loss Per Share $0.69
Nektar Therapeutics Reports First Quarter 2021 Financial Results
Nektar Therapeutics Reports Q4 2020 Financial Results
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.
455 Mission Bay Blvd S
SAN FRANCISCO, CA
Robert B. Chess
Independent Chairman of the Board
Howard W. Robin
President, Chief Executive Officer, Director
Gilbert M Labrucherie
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Jillian B. Thomsen
Senior Vice President - Finance, Chief Accounting Officer
Mark A. Wilson
Senior Vice President, General Counsel
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
A federal judge has dismissed a proposed class action accusing Nektar Therapeutics Inc of misleading investors about the results of clinical trials examining the effectiveness of its flagship cancer drug.
* NEKTAR THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM PHASE 1 DOSE-ESCALATION STUDY FOR BEMPEGALDESLEUKIN PLUS NIVOLUMAB IN 'CANCER DISCOVERY' JOURNAL Source text for Eikon: Further company coverage:
* Q1 REVENUE $50.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $47.6 MILLION
* Q4 EARNINGS PER SHARE ESTIMATE $-0.68 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:
Nektar Therapeutics said on Tuesday it was withdrawing the application for its opioid painkiller for adults with chronic low back pain, after a U.S. Food and Drug Administration (FDA) panel unanimously voted against the drug's approval.
Independent advisers to the U.S. Food and Drug Administration on Tuesday unanimously voted against Nektar Therapeutics' opioid painkiller for adults with chronic low back pain for whom currently available therapies have been inadequate.
Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.